Kronos Bio Doubles Its Cash With $155m Financing

Funding Will Back Clinical Trials For Two Lead Assets

 
• By Mandy Jackson

The cancer drug developer led by former Gilead R&D head Norbert Bischofberger will start a registrational trial for its recently acquired SYK inhibitor and the first trial for its CDK9 inhibitor.

SC2008_Different Wages_253900027_1200.jpg
Kronos more than doubled the $123m it raised previously • Source: Shutterstock

More from Financing

More from Business